Equities

Novartis AG

0QLR:LSE

Novartis AG

  • Price (CHF)93.65
  • Today's Change0.565 / 0.61%
  • Shares traded5.61k
  • 1 Year change7.21%
  • Beta--
Data delayed at least 20 minutes, as of May 17 2024 09:57 BST.
More ▼

Profile data is unavailable for this security.

About the company

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

  • Revenue in CHF (TTM)43.25bn
  • Net income in CHF8.25bn
  • Incorporated1996
  • Employees76.06k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		0QLR:LSE since
announced		Transaction
value
IFM Due IncAnnounced13 Mar 202413 Mar 2024Announced6.92%835.00m
Cytokinetics IncRumoured08 Jan 202408 Jan 2024Rumoured3.58%--
Calypso Biotech BVAnnounced08 Jan 202408 Jan 2024Announced3.58%425.00m
SanReno TherapeuticsDeal completed05 Jan 202405 Jan 2024Deal completed4.24%--
DTx Pharma IncDeal completed17 Jul 202317 Jul 2023Deal completed10.23%500.00m
Data delayed at least 20 minutes, as of May 17 2024 09:57 BST.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.